Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Neurocrine Biosciences, Inc

NBIX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Large Cap Analyst: BUY

Last Close

$152.72

▲ +1.26%

Market Cap $15.52B · Vol 346.95K

Key Metrics

P/E Ratio

22.39

FWD: 17.01

Market Cap

$15.52B

Large Cap

Div Yield

N/A

EPS Growth

+50.38%

YoY

RSI (14)

30.24

Momentum

Beta

0.37

vs Market

52W High

$186.12

17.95% below

52W Low

$122.15

25.03% above

Volume

346.95K

Avg 414.20K

P/B

4.36

Price-to-book

ROE

16.38%

Return on equity

Free Float

98.83%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Neurocrine Biosciences, Inc (NBIX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NBIX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.54%

-11.23%

-3.98%

+23.04%

YTD

+7.68%

+16.30%

+43.64%

+71.36%

Financials & Valuation

TTM · Annual

Total Revenue	$2.86B
Net Income	$478.60M
Revenue Growth (YoY)	+39.49%
Gross Margin	98.18%
Operating Margin	22.25%
Net Profit Margin	16.73%
ROE	16.38%
ROA · ROIC	16.90% · 16.38%

P/E Ratio	22.39
Forward P/E (FY1)	17.01
PEG Ratio	0.73
P/S	5.08
P/B	4.36
P/FCF	19.42
EPS Growth	+50.38%
Outstanding Shares	101.65M

Technical Indicators

50-Day SMA	$167.95
200-Day SMA	$146.86
RSI (14)	30.24
Beta	0.37
52-Week High	$186.12
52-Week Low	$122.15

Volume Today	346.95K
Avg Daily Volume (30D)	414.20K
Relative Volume	0.84x
Volatility (10D)	30.50
Volatility (30D)	42.30
Free Float	98.83%

Analyst Consensus

BUY

Current Price $152.72

Mean Target $209.01

52W Low$122.15 52W High$186.12

Current

Target

$122.15 $186.12

Current Analyst target

+36.86% upside potential · 29 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S8W4X9

ISINUS64125C1099

CountryUnited States of America

Sub-IndustryPharmaceuticals (NEC)

Earnings DateOct 26, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampator? / (AMPA PAM) and others.